Table 5.

 Analysis of primary outcome of diagnosis of diabetes in Ontario Diabetes Database by drug and dose in new users of statins. Figures are hazard ratios (95% confidence intervals)

Statin	Unadjusted	Adjusted*
Pravastatin	Reference	Reference
Atorvastatin	1.21 (1.15 to 1.28)	1.12 (1.05 to 1.18)
Fluvastatin	0.94 (0.80 to 1.10)	0.94 (0.80 to 1.11)
Lovastatin	0.96 (0.83 to 1.11)	0.99 (0.85 to 1.14)
Rosuvastatin	1.21 (1.13 to 1.30)	1.01 (0.94 to 1.09)
Simvastatin	1.16 (1.09 to 1.24)	1.11 (1.04 to 1.18)
Dose grouping:
Low dose†	Reference	Reference
Moderate dose‡	1.26 (1.22 to 1.30)	1.22 (1.19 to 1.26)
High dose§	1.39 (1.29 to 1.50)	1.30 (1.20 to 1.40)

*Adjusted for age, sex, year of cohort entry, recent acute coronary syndrome, chronic coronary artery disease, Charlson score, and previous use of diuretic (thiazide), nitroglycerin, angiotensin receptor blocker, β blocker, hormones and analogues.

†Atorvastatin <20 mg, fluvastatin all doses, lovastatin all doses, pravastatin all doses, rosuvastatin <10 mg, simvastatin <80 mg.

‡Atorvastatin 20-<80 mg, rosuvastatin 10-<40 mg, simvastatin ≥8 0mg.

§Atorvastatin ≥80 mg, rosuvastatin ≥40 mg.